Expression and significance of MMP2 and HIF-1α in hepatocellular carcinoma

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 539-546

  Wang, Bin ^a   Ding, You Ming ^a   Fan, Ping ^a   Wang, Bing ^a   Xu, Jun Hui ^a   Wang, Wei Xing ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Gene expression; Hepatocellular carcinoma; Hypoxia inducible factor 1a; Matrix metalloproteinase 2

Indexed keywords

GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR VOLUME;

EID: 84902344904     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2189     Document Type: Article

References (27)

1. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, Rodríguez-Enríquez S and Moreno-Sánchez R: HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9: 1084-1101, 2009.
2. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, Williams K, Brenot A, Gordon JI and Werb Z: Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 6: 2224-2234, 2010.
3. Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Calberg-Bacq CM, Foidart JM and Noël A: Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 8: 3450-3457, 2001.
4. Yamasaki M, Nagatomo T, Matsuyama T, Ikeho Y, Kato E, Nishiyama K, Sakakibara Y, Suiko M and Nishiyama K: Conjugated linoleic acids inhibit hypoxia inducible factor-1α stabilization under hypoxic condition in human hepatocellular carcinoma cells. J Oleo Sci 9: 491-496, 2012.
5. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 17: 4693-4696, 2000.
6. Karahan N, Güney M, Baspinar S, Oral B, Kapucuoglu N and Mungan T: Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 28: 184-188, 2007.
7. Sakata H, Fujimura M, Watanabe M and Tominaga T: Association of cavernous malformation within vestibular schwannoma: immunohistochemical analysis of matrix metalloproteinase-2 and-9. Neurol Med Chir 47: 509-512, 2007.
8. Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, Song H, Vandenberg S and Bergers G: Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol 3: 254-264, 2008.
9. Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY and Gao DM: Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 16: 5463-5472, 2011.
10. Varotti G, Ramacciato G, Ercolani G, Grazi GL, Vetrone G, Cescon M, Del Gaudio M, Ravaioli M, Ziparo V, Lauro A and Pinna A: Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol 31: 760-767, 2005.
11. Nishida Y, Miyamori H, Thompson EW, Takino T, Endo Y and Sato H: Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2. Cancer Res 21: 9096-9104, 2008.
12. Schoedel KE, Tyner VZ, Kim TH, Michalopoulos GK and Mars WM: HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Mod Pathol 1: 14-21, 2003.
13. Kato T, Kure T, Chang JH, Gabison EE, Itoh T, Itohara S and Azar DT: Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 2: 187-190, 2001.
14. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 10: 721-732, 2003.
15. Hao J, Song X, Song B, Liu Y, Wei L, Wang X and Yu J: Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 7: 449-455, 2008.
16. Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C, West CM, Williams KJ and Brabant G: Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer 1: 61-72, 2010.
17. Seeber LM, Horrée N, van der Groep P, van der Wall E, Verheijen RH and van Diest PJ: Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer 10: 307, 2010.
18. Samulitis BK, Landowski TH and Dorr RT: Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. Invest New Drugs 1: 89-98, 2009.
19. Milosevic M, Fyles A, Hedley D and Hill R: The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 3: 249-258, 2004.
20. Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK and Claffey KP: Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol Cell Biol 2: 772-783, 2008.
21. Jing SW, Wang YD, Kuroda M, Su JW, Sun GG, Liu Q, Cheng YJ and Yang CR: HIF-1α contributes to hypoxia-induced invasion and metastasis of esophageal carcinoma via inhibiting E-cadherin and promoting MMP-2 expression. Acta Med Okayama 5: 399-407, 2012.
22. Mimeault M and Batra SK: Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer-and metastasis-initiating cells. J Cell Mol Med 1: 30-54, 2013.
23. Nurwidya F, Takahashi F, Minakata K, Murakami A and Takahashi K: From tumor hypoxia to cancer progression: the implications of hypoxia-inducible factor-1 expression in cancers. Anat Cell Biol 2: 73-78, 2012.
24. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P and Semenza GL: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138-1143, 2003.
25. Xie T, Yuan XL, Yu SY, Yang B and Dong LL: Interference of HIF-1alpha by RNA reduces the expression of matrix metalloproteinase-2 in human cervical carcinoma HeLa cells. Ai Zheng 6: 600-605, 2008 (In Chinese).
26. Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V and Antonaci S: Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 4: 613-627, 2001.
27. Choi SH, Shin HW, Park JY, Yoo JY, Kim do Y, Ro WS, Yun CO and Han KH: Effects of the knockdown of hypoxia inducible factor-1alpha expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. Korean J Hepatol 3: 280-287, 2010.